POINT RICHMOND, Calif., July 5, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the JMP Securities Healthcare Conference in New York on July 12, 2012 at 4:00 p.m. ET.
A live audio webcast and replay of this presentation may be accessed at http://wsw.com/webcast/jmp18/tspt/ and on the Transcept Investor webpage at www.transcept.com.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Transcept Pharmaceuticals, Inc.
Sr. Director, Corporate Communications
SOURCE Transcept Pharmaceuticals, Inc.